| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Activity of EGFR antibody in non-V600 BRAF mutant metastatic colorectal cancer
|
Wang, Y.
|
|
|
30 |
1 |
p. 147-149
|
artikel
|
| 2 |
An adaptive population enrichment phase III trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (TAPPAS trial)
|
Mehta, C.R.
|
|
|
30 |
1 |
p. 103-108
|
artikel
|
| 3 |
Avoiding the hazards of misinterpreting treatment effects
|
Saad, E.D.
|
|
|
30 |
1 |
p. 16-18
|
artikel
|
| 4 |
Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE—a global phase III study
|
Yoshino, T.
|
|
|
30 |
1 |
p. 124-131
|
artikel
|
| 5 |
Cancer mortality and predictions for 2018 in selected Australasian countries and Russia
|
Carioli, G.
|
|
|
30 |
1 |
p. 132-142
|
artikel
|
| 6 |
Chemotherapy in localized soft tissue sarcoma: will we soon have to treat grade 1 tumors? Update on CINSARC performances
|
Valentin, T.
|
|
|
30 |
1 |
p. 153-155
|
artikel
|
| 7 |
Clearing the air: towards agreement about access to high cost cancer medicines
|
Lipworth, W.
|
|
|
30 |
1 |
p. 143-146
|
artikel
|
| 8 |
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
|
Chan, T.A.
|
|
|
30 |
1 |
p. 44-56
|
artikel
|
| 9 |
Dose tailoring of adjuvant chemotherapy for breast cancer based on hematologic toxicities: further results from the prospective PANTHER study with focus on obese patients
|
Matikas, A.
|
|
|
30 |
1 |
p. 109-114
|
artikel
|
| 10 |
Dreams can come true: the first steps toward a peripheral blood screening test for the early detection of tumors have been taken
|
Haferlach, C.
|
|
|
30 |
1 |
p. 12-13
|
artikel
|
| 11 |
Editorial board
|
|
|
|
30 |
1 |
p. ii-iii
|
artikel
|
| 12 |
Genomewide copy number alteration screening of circulating plasma DNA: potential for the detection of incipient tumors
|
Lenaerts, L.
|
|
|
30 |
1 |
p. 85-95
|
artikel
|
| 13 |
Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy
|
Chen, Y.-P.
|
|
|
30 |
1 |
p. 68-75
|
artikel
|
| 14 |
Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma
|
Oliva, M.
|
|
|
30 |
1 |
p. 57-67
|
artikel
|
| 15 |
Interpretation of time-to-event outcomes in randomized trials: an online randomized experiment
|
Weir, I.R.
|
|
|
30 |
1 |
p. 96-102
|
artikel
|
| 16 |
Leptomeningeal tumor response to combined MAPK/ERK inhibition in V600E-mutated gliomas despite undetectable CSF drug levels
|
Hottinger, A.F.
|
|
|
30 |
1 |
p. 155-156
|
artikel
|
| 17 |
Loss of function of NF1 is a mechanism of acquired resistance to endocrine therapy in lobular breast cancer
|
Sokol, E.S.
|
|
|
30 |
1 |
p. 115-123
|
artikel
|
| 18 |
Medical oncologists must get more involved in systemic treatment
|
Raoul, J.L
|
|
|
30 |
1 |
p. 6-8
|
artikel
|
| 19 |
Noninferiority for Short-HER or short-chemotherapy?
|
Aktas, B.Y.
|
|
|
30 |
1 |
p. 147
|
artikel
|
| 20 |
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS
|
Muro, K.
|
|
|
30 |
1 |
p. 19-33
|
artikel
|
| 21 |
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS
|
Muro, K.
|
|
|
30 |
1 |
p. 34-43
|
artikel
|
| 22 |
Passion for immune checkpoint blockade in triple negative breast cancer: Comment on the IMpassion130 study
|
Kok, M.
|
|
|
30 |
1 |
p. 13-16
|
artikel
|
| 23 |
Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) in the real-world setting
|
van der Galiën, H.T.
|
|
|
30 |
1 |
p. 151-152
|
artikel
|
| 24 |
Quantitative lymph node burden as a ‘very-high-risk’ factor identifying head and neck cancer patients benefiting from postoperative chemoradiation
|
Zumsteg, Z.S.
|
|
|
30 |
1 |
p. 76-84
|
artikel
|
| 25 |
Reply to the letter to the editor ‘Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) in the real-world setting’ by van der Galiën et al.
|
Maurer, M.J.
|
|
|
30 |
1 |
p. 153
|
artikel
|
| 26 |
Reply to the letter to the editor ‘Response to the effect of PD-L1 testing on the cost-effectiveness of immune checkpoint inhibitors’ by Ogale
|
de Lima Lopes, G.
|
|
|
30 |
1 |
p. 149-150
|
artikel
|
| 27 |
Table of Contents
|
|
|
|
30 |
1 |
p. iv-v
|
artikel
|
| 28 |
Thanks to referees 2018
|
|
|
|
30 |
1 |
p. 1-5
|
artikel
|
| 29 |
Treatable causes of diarrhoea in patients on tyrosine kinase inhibitors for metastatic renal cell carcinoma
|
Lightowlers, S.V.
|
|
|
30 |
1 |
p. 150-151
|
artikel
|
| 30 |
Virtual microdissection in the molecular subtyping of head and neck squamous carcinoma—a ‘Virtual Reality’ of the tumor microenvironment?
|
Ma, B.B.Y.
|
|
|
30 |
1 |
p. 8-10
|
artikel
|
| 31 |
Weighing false hope in population anticancer drug decision making
|
Chamberlain, C.
|
|
|
30 |
1 |
p. 10-11
|
artikel
|
Tijdschrift beschrijving